NEW YORK, May 1 - Exelixis and pharma giant Merck will design and develop small-molecule compound libraries for high-throughput drug screening, Exelixis said today.
Both firms will own the libraries, which will be used for internal lead-discovery programs as well as in collaborative research ventures, the partners said.
Exelixis will bring to the table small molecules, analytics, informatics, and formatting.
Click here for more information.